Effect of Dextran Sulfate (MDS) on Prevention of Ischemic Heart Disease in Double Blind Primary Prevention Trial

抄録

A primary prevention study based on the double blind method was conducted to clarify both the improvement of serum lipid levels and the prevention of the arteriosclerotic diseases through the long-term administration (3 to 5 years) of MDS (1, 800mg per day) to male subjects with asymptomatic hyperlipidemia (136 in MDS group, 136 in control group), whose ages ranged from 30 to 60 years old. During the study, four ischemic heart diseases occurred in the control group, while no such diseases occurred in the MDS group. Thus, the incidence of ischemic heart diseases was significantly lowered in the MDS group, in which serum lipid levels in type II_a and type II_b hyperlipidemia were significantly lowered. The first primary prevention study for the arteriosclerotic diseases through the double blind method in Japan proved that the long-term administration of MDS at 1, 800mg per day was useful for improving serum lipid levels, and effective for the primary prevention of ischemic heart diseases such as myocardial infarction and angina pectoris.